Ultrasound response to tofacitinib in patients with rheumatoid arthritis: Data from a multicenter 24 weeks prospective study.
OMERACT
clinical remission
rheumatoid arthritis
tofacitinib
ultrasonography
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
07
2022
accepted:
08
09
2022
entrez:
13
10
2022
pubmed:
14
10
2022
medline:
14
10
2022
Statut:
epublish
Résumé
Treatment of rheumatoid arthritis (RA) should aim at full remission. Ultrasonography (US) might have an added value to clinical examination in assessing disease activity of RA. In this study we evaluated the ultrasound response, next to clinical and laboratory response, in RA patients treated with tofacitinib (TOF). In this observational multicenter study, patients received TOF 5 mg twice daily, with or without the contemporary use of methotrexate or other conventional DMARD, for 24 weeks. All patients underwent clinical, laboratory and US examinations of 40 sites among joints and tendons. Sonographers were blinded to clinical and laboratory parameters. Data were assessed at baseline, week 2, 4, 8, 12 and 24. For each patient we used two US joint scores (Gray Scale -GS-and power Doppler -PD- score), a 0-3 semi-quantitative scale for each joint and the EULAR-OMERACT US scoring system (combined GS and PD graded from 0 to 3). Besides, we calculated a tenosynovitis scores (GS and PD) according to the OMERACT score. Fifty-two RA patients completed the 6 months period study: mean disease duration 9.97 ± 8.75 years, baseline DAS28-CRP 4.9 ± 1.2, HAQ 1.4 ± 0.7, C-reactive protein (CRP 2.25 ± 3.11 mg/dl). Baseline joint (GS, PD and combined-US) and tendon US scores (GS and PD) were 23.5 ± 18.4, 22.7 ± 19.3, 25.7 ± 20.6, 10.5 ± 11.4 and 11.0 ± 12.0, respectively. US joint and tendon scores significantly reduced as early as T1 (week 2) examination as well as at week 4, 12 and 24, as compared to baseline values ( These results provide evidence that TOF treatment leads to early (2 weeks) and persistent reduction of US signs of inflammation both at tendon and joint level comparable to clinical improvement.
Sections du résumé
Background
UNASSIGNED
Treatment of rheumatoid arthritis (RA) should aim at full remission. Ultrasonography (US) might have an added value to clinical examination in assessing disease activity of RA. In this study we evaluated the ultrasound response, next to clinical and laboratory response, in RA patients treated with tofacitinib (TOF).
Methods
UNASSIGNED
In this observational multicenter study, patients received TOF 5 mg twice daily, with or without the contemporary use of methotrexate or other conventional DMARD, for 24 weeks. All patients underwent clinical, laboratory and US examinations of 40 sites among joints and tendons. Sonographers were blinded to clinical and laboratory parameters. Data were assessed at baseline, week 2, 4, 8, 12 and 24. For each patient we used two US joint scores (Gray Scale -GS-and power Doppler -PD- score), a 0-3 semi-quantitative scale for each joint and the EULAR-OMERACT US scoring system (combined GS and PD graded from 0 to 3). Besides, we calculated a tenosynovitis scores (GS and PD) according to the OMERACT score.
Results
UNASSIGNED
Fifty-two RA patients completed the 6 months period study: mean disease duration 9.97 ± 8.75 years, baseline DAS28-CRP 4.9 ± 1.2, HAQ 1.4 ± 0.7, C-reactive protein (CRP 2.25 ± 3.11 mg/dl). Baseline joint (GS, PD and combined-US) and tendon US scores (GS and PD) were 23.5 ± 18.4, 22.7 ± 19.3, 25.7 ± 20.6, 10.5 ± 11.4 and 11.0 ± 12.0, respectively. US joint and tendon scores significantly reduced as early as T1 (week 2) examination as well as at week 4, 12 and 24, as compared to baseline values (
Conclusion
UNASSIGNED
These results provide evidence that TOF treatment leads to early (2 weeks) and persistent reduction of US signs of inflammation both at tendon and joint level comparable to clinical improvement.
Identifiants
pubmed: 36226143
doi: 10.3389/fmed.2022.990317
pmc: PMC9549158
doi:
Types de publication
Journal Article
Langues
eng
Pagination
990317Informations de copyright
Copyright © 2022 Germanò, Macchioni, Maranini, Ciancio, Bonazza, Govoni and Salvarani.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Arthritis Rheum. 2008 Oct;58(10):2958-67
pubmed: 18821687
N Engl J Med. 2012 Aug 9;367(6):495-507
pubmed: 22873530
Ann Rheum Dis. 2016 Oct;75(10):1763-9
pubmed: 26590174
Arthritis Rheum. 2008 Aug;58(8):2248-56
pubmed: 18668537
Rheumatology (Oxford). 2016 Oct;55(10):1826-36
pubmed: 27354688
Arthritis Res Ther. 2018 Jan 30;20(1):15
pubmed: 29382379
Rheumatology (Oxford). 2012 Sep;51(9):1655-61
pubmed: 22627728
Ann Rheum Dis. 2005 Mar;64(3):375-81
pubmed: 15708891
RMD Open. 2017 Jul 11;3(1):e000428
pubmed: 28948983
Clin Exp Rheumatol. 2022 May;40(5):921-927
pubmed: 34251313
Ann Rheum Dis. 2013 Jun;72(6):804-14
pubmed: 23520036
Joint Bone Spine. 2020 Jan;87(1):57-62
pubmed: 31557525
Ann Rheum Dis. 2011 Nov;70(11):1995-8
pubmed: 21784724
Clin Rheumatol. 2018 Apr;37(4):1111-1114
pubmed: 29181728
Nat Rev Rheumatol. 2021 Jan;17(1):17-33
pubmed: 33293696
BioDrugs. 2016 Oct;30(5):407-419
pubmed: 27577235
Rheumatology (Oxford). 2016 Jan;55(1):89-93
pubmed: 26316580
Ther Adv Musculoskelet Dis. 2020 May 11;12:1759720X20915322
pubmed: 32523635
RMD Open. 2017 Jul 11;3(1):e000427
pubmed: 28948984
Arthritis Rheumatol. 2016 Nov;68(11):2584-2592
pubmed: 27214046
Ann Rheum Dis. 2001 Jul;60(7):641-9
pubmed: 11406516
Ann Rheum Dis. 2006 Dec;65(12):1658-60
pubmed: 16728459
Arthritis Rheumatol. 2019 Jun;71(6):878-891
pubmed: 30666826
Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77
pubmed: 24818516
Lancet. 2013 Feb 9;381(9865):451-60
pubmed: 23294500
Arthritis Rheum. 2013 Jul;65(7):1694-701
pubmed: 23553120
J Rheumatol. 2018 Feb;45(2):165-169
pubmed: 29247153
Front Med (Lausanne). 2018 Mar 08;5:40
pubmed: 29662880
Nat Rev Rheumatol. 2017 May;13(5):320
pubmed: 28360424
Arthritis Res Ther. 2018 Oct 3;20(1):224
pubmed: 30285845
Ann Rheum Dis. 2011 Mar;70(3):404-13
pubmed: 21292833
BMC Rheumatol. 2020 Oct 19;4:55
pubmed: 33089069
J Rheumatol. 2009 Dec;36(12):2788-94
pubmed: 19918042
Lancet. 2017 Jul 29;390(10093):457-468
pubmed: 28629665
Clin Exp Rheumatol. 2003 Sep-Oct;21(5):632-4
pubmed: 14611113
Ann Rheum Dis. 2017 Dec;76(12):1974-1979
pubmed: 28814430
RMD Open. 2019 Jan 11;5(1):e000806
pubmed: 30713721
Ann Rheum Dis. 2020 Jun;79(6):685-699
pubmed: 31969328
Arthritis Rheum. 2009 Jul;60(7):1915-22
pubmed: 19565512
RMD Open. 2019 Jun 25;5(2):e000950
pubmed: 31321076
Rheumatology (Oxford). 2012 Dec;51 Suppl 6:vi5-9
pubmed: 23221588